ADC Datopomab Deruxtecan Shows Responses Across Doses in Advanced NSCLC
January 31st 2021Datopotamab deruxtecan showed antitumor activity in the treatment of patients with advanced or metastatic non–small cell lung cancer, according to updated results of the phase 1 TROPION-PanTumor01 trial.
Read More
Addition of Ipilimumab to Pembrolizumab Not Additive in Frontline PD-L1–High NSCLC
January 31st 2021Survival was not improved with the immunotherapy combination of pembrolizumab and ipilimumab in comparison with pembrolizumab monotherapy in the first-line treatment of patients with metastatic non–small cell lung cancer who had high PD-L1 expression and did not harbor EGFR or ALK aberrations, findings from the phase 3 KEYNOTE-598 trial showed.
Read More
Response and Resection Rates Following Neoadjuvant Atezolizumab Impress in Resectable NSCLC
January 30th 2021Neoadjuvant atezolizumab followed by surgery led to a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, according to findings from the primary analysis of the LCMC3 trial.
Read More
DFS Prolonged With Adjuvant Osimertinib Despite Prior Adjuvant Chemo in EGFR+ NSCLC
January 29th 2021In patients with EGFR-mutated non–small cell lung cancer, adjuvant treatment with osimertinib in the pivotal phase 3 ADAURA trial led to improvement in disease-free survival, irrespective of previous adjuvant chemotherapy received or disease stage.
Read More
Outcomes of Larotretinib Confirmed in TRK Fusion-Positive Lung Cancer
January 29th 2021Lyudmila A. Bazhenova, MD, explains the impact of having larotrectinib results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer Singapore.
Read More
Encouraging Activity Shown With Trastuzumab Deruxtecan in HER2-Overexpressing NSCLC
January 29th 2021Antitumor activity was demonstrated with trastuzumab deruxtecan treatment in patients with HER2-overexpressing non–small cell lung cancer, regardless of HER2 expression levels, according to interim findings from a cohort of the phase 2 DESTINY Lung-01 trial.
Read More
Nab-Paclitaxel Demonstrates Noninferiority to Docetaxel in Previously Treated Patients With NSCLC
January 29th 2021Progression-free survival and overall survival benefits, combined with a higher objective response rate, confirmed the noninferiority of nab-paclitaxel compared with docetaxel in previously treated patients with advanced non–small cell lung cancer, according to phase 3 trial results.
Read More
Promising Results Seen With Pembrolizumab Plus Chemoradiation in Stage III NSCLC
January 29th 2021Antitumor activity was seen in the combination of pembrolizumab plus concurrent chemoradiation therapy in patients with unresectable, locally advanced, stage III non-small cell lung cancer, regardless of PD-L1 status or tumor histology.
Read More
Amivantamab Achieves Promising Efficacy Outcomes in Previously Treated EGFR Exon 20+ NSCLC
January 29th 2021Treatment with amivantamab induced deep and durable responses as well as promising survival as treatment of patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutation in phase 1 CHRYSALIS trial.
Read More
Bemcentinib/Pembrolizumab Shows Clinical Activity, Tolerability in Advanced NSCLC
January 29th 2021Patients with checkpoint inhibitor-naïve and refractory composite AXL-positive non—small cell lung cancer, responded to treatmen with the first-in-class oral kinase inhibitor bemcentinib in combination with pembrolizumab, and the compound was well-tolerated, according to updated results from the phase 2 BGBC008 clinical trial.
Read More
Sotorasib Impresses in KRAS G12C–Mutant Non–Small Cell Lung Cancer
January 29th 2021Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer, according to results from the phase 2 portion of the CodeBreaK 100 trial to be presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer.
Read More
Liposomal Irinotecan Demonstrates Safety, Efficacy in Adults with SCLC After IL Chemo Failure
January 28th 2021In the phase 1 RESILIENT trial, patients with small cell lung cancer who failed platinum-based treatment in the first-line setting, displayed encouraging anti-tumor activity and safety, results presented during the 2020 World Conference on Lung Cancer show.
Read More
BMS-986012 Combined With Nivolumab Demonstrates Preliminary Efficacy in Relapsed/Refractory SCLC
January 28th 2021In patients with relapsed/refractory small cell lung cancer who did not receive previous checkpoint inhibitor therapy, the addition of the anti–fucosyl-GM1 monoclonal antibody, BMS-986012 to nivolumab demonstrated promising results in a phase 1/2 study.
Read More
Pembrolizumab Further Improves Outcomes in PD-L1+ Locally Advanced/Metastatic NSCLC
January 28th 2021Long-term follow-up results from KEYNOTE-042 show that pembrolizumab continues to improve survival and response outcomes in patients with PD-L1+ locally advanced or metastatic non–small cell lung cancer.
Read More
Benefit of Pembrolizumab and Chemotherapy Maintained in Nonsquamous NSCLC Population
January 28th 2021Overall survival is significantly improved when pembrolizumab is added to platinum-based chemotherapy in the frontline treatment of patients with metastatic nonsquamous non-small cell lung cancer.
Read More
Apatinib/Chemotherapy Demonstrates Encouraging Efficacy, Tolerability in Advanced SCLC
January 28th 2021In pretreated patients with advanced small cell lung cancer, treatment with the combination of apatinib and single-agent chemotherapy showed promising efficacy and was well-tolerated, data from a prospective phase 2 study.
Read More
Immunotherapy and Targeted Therapy Triplet Active in Microsatellite Stable mCRC
January 27th 2021The triplet regimen of nivolumab, ipilimumab, and panitumumab has shown antitumor activity among patients with previously treated metastatic colorectal cancer that is microsatellite stable and KRAS, NRAS, and BRAF wild-type, according to findings from a phase 2 LCCC1632 study.
Read More
Health-Related Quality of Life Low in Younger Colorectal Cancer Survivors
January 18th 2021The overall health-related quality of life among younger patients with colorectal cancer is poorer as incidence in patients under the age of 50 increases, with social and functional well-being suffering more with longer treatment durations.
Read More